Pharvaris (PHVS) Liabilities and Shareholders Equity (2019 - 2026)
Pharvaris (PHVS) posted Liabilities and Shareholders Equity of $304.1 million for Q1 2026, down 13.33% on a QoQ basis from $350.9 million in Q4 2025, and up 16.56% year-over-year from $260.9 million in Q1 2025.
Pharvaris (PHVS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Pharvaris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $304.1 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 16.56% year-over-year to $304.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed 0.49% YoY) and the FY2025 annual result came in at $340.6 million, up 8.0% from the prior year.
- Liabilities and Shareholders Equity was $304.1 million for Q1 2026 at Pharvaris, down from $350.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $429.0 million in Q4 2023 and bottomed at $158.6 million in Q1 2023.
- A 5-year average of $282.0 million and a median of $260.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 158.58% — and 2025, when it tumbled 37.32%.
- Pharvaris' Liabilities and Shareholders Equity stood at $171.1 million in 2022, then jumped by 150.67% to $429.0 million in 2023, then decreased by 27.42% to $311.4 million in 2024, then grew by 12.7% to $350.9 million in 2025, then declined by 13.33% to $304.1 million in 2026.
- Business Quant data shows PHVS's Liabilities and Shareholders Equity at $304.1 million in Q1 2026, $350.9 million in Q4 2025, and $396.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.25 Bn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | 304.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.15 Mn |
| Dec 31, 2025 | 350.91 Mn |
| Sep 30, 2025 | 396.19 Mn |
| Jun 30, 2025 | 237.50 Mn |
| Mar 31, 2025 | 260.93 Mn |
| Dec 31, 2024 | 311.36 Mn |
| Sep 30, 2024 | 343.94 Mn |
| Jun 30, 2024 | 378.90 Mn |
| Mar 31, 2024 | 410.20 Mn |
| Dec 31, 2023 | 428.97 Mn |
| Sep 30, 2023 | 184.34 Mn |
| Jun 30, 2023 | 206.62 Mn |
| Mar 31, 2023 | 158.64 Mn |
| Dec 31, 2022 | 171.13 Mn |
| Sep 30, 2022 | 204.66 Mn |
| Jun 30, 2022 | 220.61 Mn |
| Mar 31, 2022 | 225.74 Mn |
| Dec 31, 2021 | 242.62 Mn |
| Sep 30, 2021 | 263.09 Mn |
| Jun 30, 2021 | 276.65 Mn |